Alcon Inc. reported second-quarter 2026 net sales of $2.8 billion, an 8% increase from the prior year period. Diluted earnings per share were $0.00, primarily due to a pre-tax, non-cash charge of $402 million related to the discontinuation of PowerVision IOL programs. Core diluted EPS rose 11% to $0.84. The company returned $538 million to shareholders year-to-date through dividends and share repurchases, with approximately $1.2 billion remaining under its authorization. Alcon raised its full-year core operating margin growth guidance to +90 to +190 basis points and core diluted EPS growth to +12% to +15%. The company operates in the eye care industry, providing surgical equipment, implantables, consumables, contact lenses, and ocular health products.